Anti-cytokine therapies in T1D: Concepts and strategies

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Anti-cytokine therapies in T1D : Concepts and strategies. / Nepom, Gerald T; Ehlers, Mario; Mandrup-Poulsen, Thomas.

In: Clinical Immunology, Vol. 149, No. 3 Part A, 12.2013, p. 279-85.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Nepom, GT, Ehlers, M & Mandrup-Poulsen, T 2013, 'Anti-cytokine therapies in T1D: Concepts and strategies', Clinical Immunology, vol. 149, no. 3 Part A, pp. 279-85. https://doi.org/10.1016/j.clim.2013.02.003

APA

Nepom, G. T., Ehlers, M., & Mandrup-Poulsen, T. (2013). Anti-cytokine therapies in T1D: Concepts and strategies. Clinical Immunology, 149(3 Part A), 279-85. https://doi.org/10.1016/j.clim.2013.02.003

Vancouver

Nepom GT, Ehlers M, Mandrup-Poulsen T. Anti-cytokine therapies in T1D: Concepts and strategies. Clinical Immunology. 2013 Dec;149(3 Part A):279-85. https://doi.org/10.1016/j.clim.2013.02.003

Author

Nepom, Gerald T ; Ehlers, Mario ; Mandrup-Poulsen, Thomas. / Anti-cytokine therapies in T1D : Concepts and strategies. In: Clinical Immunology. 2013 ; Vol. 149, No. 3 Part A. pp. 279-85.

Bibtex

@article{36d6efb874d544c6bf6c25bdb4656ed7,
title = "Anti-cytokine therapies in T1D: Concepts and strategies",
abstract = "Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.",
keywords = "Antibodies, Monoclonal, Clinical Trials as Topic, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Immunotherapy, Interleukin-1, Interleukin-12, Interleukin-23, Interleukin-6, T-Lymphocytes, Regulatory, Tumor Necrosis Factor-alpha",
author = "Nepom, {Gerald T} and Mario Ehlers and Thomas Mandrup-Poulsen",
note = "Copyright {\textcopyright} 2013 Elsevier Inc. All rights reserved.",
year = "2013",
month = dec,
doi = "10.1016/j.clim.2013.02.003",
language = "English",
volume = "149",
pages = "279--85",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press",
number = "3 Part A",

}

RIS

TY - JOUR

T1 - Anti-cytokine therapies in T1D

T2 - Concepts and strategies

AU - Nepom, Gerald T

AU - Ehlers, Mario

AU - Mandrup-Poulsen, Thomas

N1 - Copyright © 2013 Elsevier Inc. All rights reserved.

PY - 2013/12

Y1 - 2013/12

N2 - Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.

AB - Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.

KW - Antibodies, Monoclonal

KW - Clinical Trials as Topic

KW - Diabetes Mellitus, Type 1

KW - Humans

KW - Hypoglycemic Agents

KW - Immunotherapy

KW - Interleukin-1

KW - Interleukin-12

KW - Interleukin-23

KW - Interleukin-6

KW - T-Lymphocytes, Regulatory

KW - Tumor Necrosis Factor-alpha

U2 - 10.1016/j.clim.2013.02.003

DO - 10.1016/j.clim.2013.02.003

M3 - Journal article

C2 - 23510726

VL - 149

SP - 279

EP - 285

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3 Part A

ER -

ID: 113810511